ABSTRACT

Purpose: To evaluate the status of number 3b lymph node (LN) station in patients with adenocarcinoma of the esophagogastric junction (AEG) and to investigate the optimal indications for radical proximal gastrectomy (PG) for AEG.

Materials and Methods: Data of 51 patients with clinically advanced Siewert types II and III AEG who underwent total gastrectomy (TG) between April 2010 and July 2017 were reviewed. The proportion of metastatic LNs at each LN station was examined. Number 3 LN station was separately classified into number 3a and number 3b. The risk factors for number 3b LN metastasis and the clinicopathological features of number 3b-positive AEG patients were investigated.

Results: The incidences of LN metastasis were the highest in number 1 (47.1%), followed by number 2 (23.5%), number 3a (39.2%), and number 7 (23.5%) LN stations. LN metastasis in number 3b LN station was detected in 4 patients (7.8%). A gastric invasion length of more than 40 mm was a significant risk factor for number 3b LN metastasis. All 4 patients with number 3b-positive AEG had advanced cancer with a gastric invasion length of more than 40 mm. The 5-year survival rate of patients with a gastric invasion length of more than 40 mm was 50.0%.

Conclusions: Radical PG may be indicated for patients with AEG with gastric invasion length of less than 40 mm.

Keywords: Adenocarcinoma of the esophagogastric junction; Proximal gastrectomy; Lesser curvature lymph nodes; Esophagogastric junction

INTRODUCTION

The incidence of adenocarcinoma of the esophagogastric junction (AEG) has been increasing in recent years, both in western [1,2] and in eastern [3] countries. According to the Japanese Gastric Cancer Guideline (JGCG), no consensus was reached regarding the type of gastric resection or the extent of lymphadenectomy for AEG [4]. The guideline recommends number 1, 2, 3, 7, and 9 lymph node (LN) dissection, but does not provide any specific recommendation with respect to the type of gastric resection. In practice, proximal gastrectomy (PG) is performed for both early and advanced AEG as radical gastrectomy.
The number of PGs for AEG is increasing, as it represents a function-preserving and less invasive surgery, yielding an improved postoperative quality of life [6]. However, the oncological safety of PG for AEG still remains unclear. PG would be oncologically appropriate for cases of AEG that do not need number 3b LN dissection, because the dissection of the number 3 LNs is incomplete at their distal extent in PG. In this study [7], we focused on the number 3b LN status in patients with Siewert types II and III AEG, and investigated the optimal indications for radical PG in patients with AEG.

MATERIALS AND METHODS

Patients
Between April 2010 and July 2017, 2,492 patients with gastric cancer underwent gastrectomy at the National Cancer Center Research Hospital, Tokyo, Japan. The data of 68 patients who underwent TG for advanced AEG clinically diagnosed as Siewert type II and III were reviewed. Patients who had received preoperative chemotherapy (n=12), and those who had concurrently undergone esophagectomy for esophageal cancer (n=2) were excluded. Patients with AEG and a prominent squamous component (n=2) or Siewert type I AEG (n=1) by histopathological examination were also excluded. The remaining 51 patients were included in the present study. The study was conducted with the approval of our Institutional Review Board (Ethics Committee of National Cancer Center, 2017-077).

Human rights statement and informed consent
All performed procedures were in accordance with ethical standards of the responsible committee on human experimentation (institutional and national), and with the Helsinki Declaration of 1964 and later versions. Informed consent or a substitute for it was obtained from all patients prior to their inclusion in the study.

Preparation for LN examination
All regional LNs were retrieved from the adipose connective tissue of the resected surgical specimen immediately after the surgery. The surgeons assigned the LN stations postoperatively from the en bloc specimen. Number 3 station was subclassified into number 3a (along the left gastric artery [LGA]) and number 3b (along the right gastric artery [RGA]) substations according to the Japanese Gastric Cancer Association (JGCA) recommendations from March 2010. With the introduction of this subclassification, we analyzed number 3a and 3b LN stations separately according to the JGCA guideline. Nodes found at substations number 3a and 3b were individually labeled according to the recommendation of the JGCA guideline and sent for histopathological examination together with other dissected LNs.

Description of the tumor location
After formalin fixation, the tumor size and the length of gastric and esophageal invasion were measured. The tumors were classified according to the localization of the tumor center as follows:

- Type I: 1 to 5 cm above the esophagogastric junction (EGJ)
- Type II: 1 cm above to 2 cm below the EGJ
- Type III: 2 to 5 cm below the EGJ.
Statistical analysis
Categorical data were compared using Fisher's exact test. Other variables were compared using the Mann-Whitney U test. All P values <0.05 were considered statistically significant. All analyses were performed using the SPSS statistical software (ver. 22; SPSS Inc., Chicago, IL, USA).

RESULTS

Patient characteristics
The characteristics of the patients are described in Table 1. Histopathological examination revealed early AEG in 5 patients (9.8%) and advanced AEG in the remaining 46 patients (90.2%). Regional LN metastasis was detected in 36 patients (70.6%). Siewert types II and III AEG was found in 33 patients (64.7%) and 18 patients (35.3%), respectively. The lengths of esophageal invasion and gastric invasion were 10 (range, 10–55) mm and 37 (range, 6–90) mm, respectively.

Table 1. Patient characteristics

| Variables                              | Entire cohort (n = 51) |
|----------------------------------------|------------------------|
| Sex                                    |                        |
| Male                                   | 38                     |
| Female                                 | 13                     |
| Age (years)                            | 66 (24–86)             |
| Tumor depth (pathological)             |                        |
| T1                                     | 5                      |
| T2                                     | 12                     |
| T3                                     | 25                     |
| T4                                     | 9                      |
| Nodal status (pathological)            |                        |
| N0                                     | 15                     |
| N1                                     | 14                     |
| N2                                     | 11                     |
| N3                                     | 11                     |
| Macroscopic type                       |                        |
| Type 0                                 | 16                     |
| Type 1                                 | 4                      |
| Type 2                                 | 17                     |
| Type 3                                 | 13                     |
| Type 4                                 | 1                      |
| Siewert type                           |                        |
| II                                     | 33                     |
| III                                    | 18                     |
| Tumor size (mm)                        | 58 (23–120)            |
| Esophageal invasion (mm)               | 10 (0–55)              |
| Gastric invasion (mm)                  | 37 (6–90)              |
| Circumferential distribution           |                        |
| Lesser curvature (+)                   | 43                     |
| Lesser curvature (−)                   | 8                      |
| Histological type                      |                        |
| Differentiated                         | 23                     |
| Undifferentiated                       | 28                     |
| Approach                               |                        |
| Abdominal                              | 48                     |
| Thoracoabdominal                       | 3                      |

Values are expressed as number and median values (range).
Status of LN metastasis

The incidence of metastasis was highest in number 1 (47.1%), 2 (23.5%), 3a (39.2%), and 7 (23.5%) LN stations. Although number 3a LN metastasis was detected in 20 patients (39.2%), only 4 patients (7.8%) showed number 3b LN metastasis. No LN metastasis was found in number 4d, 5, and 6 LN stations (Table 2).

Univariate analysis to identify the risk factors for number 3b LN metastasis

The incidence of number 3b LN metastasis was significantly higher in patients with AEG and a length of gastric invasion of more than 40 mm (Table 3).

Clinicopathological features of number 3b-positive AEG

Table 4 shows detailed clinicopathological features of patients with AEG and number 3b LN metastasis. All four patients had advanced AEG. In all four patients, the tumors were more than 40 mm in diameter. One patient had Siewert type II AEG and 3 patients had Siewert type III AEG. Furthermore, all patients showed a gastric invasion length of more than 40 mm and invasion of the lesser curvature. All patients had undergone TG with D2 lymphadenectomy. Two patients died of gastric cancer recurrence. The 5-year survival rate of patients with a gastric invasion length of more than 40 mm was 50.0% (Table 4).

DISCUSSION

In this study, the proportion of patients with LN metastasis was 20.0% for early AEG and 76.1% for advanced AEG. The observed incidence of LN metastasis has been reported to be much higher in patients with AEG than in patients with non-junctional cancer [8]. Therefore, complete dissection of the LNs is necessary in order to improve the survival outcomes of patients with both early and advanced AEG.

In this study, LN metastasis in stations number 1, 2, 3, and 7 was frequent in both patients with Siewert types II and III AEG. On the other hand, no cases of LN metastasis in station number 4d, 5, or 6 were detected.
Table 3. Correlations between risk factors and the incidence of number 3b lymph node metastasis

| Variables                        | Total | Number 3b metastasis-positive | Incidence of Number 3b metastasis | P value |
|----------------------------------|-------|-------------------------------|-----------------------------------|---------|
| Sex                              |       |                               |                                   |         |
| Male                             | 37    | 4                             | 10.8%                             | 0.264   |
| Female                           | 14    | 0                             | 0.0%                              |         |
| Age (years)                      |       |                               |                                   |         |
| >65                              | 28    | 2                             | 7.1%                              | 0.617   |
| <65                              | 23    | 2                             | 8.7%                              |         |
| Macroscopic type                 |       |                               |                                   | 0.300   |
| Type 0–2                         | 37    | 2                             | 5.4%                              |         |
| Type 3, 4, and 5                 | 14    | 2                             | 14.3%                             |         |
| T stage                          |       |                               |                                   |         |
| T1                               | 5     | 0                             | 0.0%                              | 0.653   |
| T2, T3, and T4                   | 46    | 4                             | 8.7%                              |         |
| Siewert type                     |       |                               |                                   | 0.120   |
| II                               | 33    | 1                             | 3.0%                              |         |
| III                              | 18    | 3                             | 16.7%                             |         |
| Esophageal invasion (mm)         |       |                               |                                   | 0.264   |
| ≥20                              | 14    | 0                             | 0.0%                              |         |
| <20                              | 37    | 4                             | 10.8%                             |         |
| Gastric invasion length (mm)     |       |                               |                                   | 0.043   |
| ≥40                              | 24    | 4                             | 16.7%                             |         |
| <40                              | 27    | 0                             | 0.0%                              |         |
| Tumor size (mm)                  |       |                               |                                   | 0.405   |
| ≥40                              | 41    | 4                             | 9.8%                              |         |
| <40                              | 10    | 0                             | 0.0%                              |         |
| Invasion of the lesser curvature |       |                               |                                   | 0.494   |
| (+)                              | 43    | 4                             | 9.3%                              |         |
| (−)                              | 8     | 0                             | 0.0%                              |         |
| Histological type                |       |                               |                                   | 0.290   |
| Differentiated                   | 25    | 3                             | 12.0%                             |         |
| Undifferentiated                 | 26    | 1                             | 3.8%                              |         |
| Lymphatic invasion involvement   |       |                               |                                   | 0.186   |
| Present                          | 34    | 4                             | 11.8%                             |         |
| Absent                           | 17    | 0                             | 0.0%                              |         |
| Venous invasion                  |       |                               |                                   | 0.494   |
| Present                          | 43    | 4                             | 9.3%                              |         |
| Absent                           | 8     | 0                             | 0.0%                              |         |
| Neural invasion                  |       |                               |                                   | 0.261   |
| Present                          | 24    | 3                             | 12.5%                             |         |
| Absent                           | 27    | 1                             | 3.7%                              |         |

Table 4. Clinicopathological features of number 3b-positive adenocarcinomas of the esophagogastric junction

| Variables                        | Case 1 | Case 2 | Case 3 | Case 4 |
|----------------------------------|--------|--------|--------|--------|
| Macroscopic type                 | Type 3 | Type 3 | Type 2 | Type 0–1lc |
| Tumor depth                      | T3     | T3     | T3     | T3     |
| Location                         | Circ   | Less   | Less   | Less   |
| Siewert type                     | II     | III    | III    | III    |
| Tumor size (mm)                  | 55     | 61     | 74     | 90     |
| Gastric invasion (mm)            | 43     | 57     | 74     | 45     |
| Histological type                | tub1   | por1   | tub2   | tub2   |
| Lymphatic invasion               | present| present| present| present|
| Venous invasion                  | present| present| present| absent  |
| Neural invasion                  | present| present| absent  | present|
| Survival                         | 60 months dead (recurrence) | 12 months dead (recurrence) | 36 months (no recurrence) | 8 months (no recurrence) |

Circ = circumferential; Less = lesser curvature.
In previous studies, the incidence of LN metastasis and the index of estimated benefit from LN dissection (IEBLD) were reported to be higher for LN stations number 1, 2, 3, and 7, and lower (or zero) for LN stations number 4d, 5, and 6, both in patients with Siewert types II and III AEG [8-11]. However, LN metastasis in stations number 4d, 5, and 6 has been reportedly detected in some patients with Siewert type III [8,11]. Therefore, caution must be exercised while evaluating patients with AEG showing invasion up to the middle-third of the stomach, because the lower perigastric LNs could be involved, even if the primary tumor epicenter is located within the upper-third of the stomach.

We further investigated the significance of metastasis in LN stations number 3a and 3b separately. The incidence of metastasis in LN station number 3a was higher in both Siewert types II and III AEG. Therefore, radical dissection of the LNs in stations number 1, 2, 3a, and 7 is important in patients with AEG.

On the other hand, the frequency of metastasis in LN station number 3b was relatively low, although not zero, in patients with AEG. Number 3b is the most important LN station while discussing the indications of PG for AEG. However, the LN status of number 3b station in AEG has not yet been investigated in detail.

Four patients in this study had metastasis in number 3b LNs. All patients with number 3b LN metastasis had a gastric invasion length of more than 40 mm, including 1 patient with Siewert type II AEG and a gastric invasion length of 55 mm. The proportion of patients with number 3b LN metastasis in patients with AEG and a gastric invasion length of more than 40 mm was 16.7%, and 1 of 4 patients with number 3b LN metastasis died within 1 year. The prognosis of patients with AEG and number 3b LN metastasis is expected to be worse even after complete LN dissection. However, the number of patients examined in this study was too small to discuss the therapeutic efficacy of number 3b LN dissection. Based on the results of this study, we suppose that the main prognostic factor related to number 3b LN metastasis is not the location of the tumor epicenter, but the lowest level of the tumor.

Although both number 3a and 3b LNs belong to number 3 region along the lesser curvature, number 3a station represents the area along the LGA and number 3b station represents the area along the RGA [12]. These two arteries are different in terms of embryological origin, with LGA and RGA deriving from the dorsal and ventral mesogastrium, respectively [13]. Considering the direction of the lymphatic flow, the lymphatics from AEG with a gastric invasion length of less than 40 mm will drain into the proximal lesser curvature nodes (number 3a station), and then to the nodes alongside the root of the LGA (number 7 station) and the celiac trunk (number 9 station), rather than to the nodes along the RGA (number 3b station). This is why number 3b LN metastasis is rare in AEG, despite the high incidence of number 3a and 7 LN metastasis.

Function-preserving gastric cancer surgery, such as PG or pylorus-preserving gastrectomy, is widely practiced for stage I disease [6,14,15]. Many retrospective studies have shown the functional benefit and oncological safety of function-preserving gastrectomy, which is associated with a lower complication rate and improved postoperative quality of life [16-18]. PG is now regarded as one of the standard procedures for early gastric cancer located in the upper-third of the stomach [4]. In practice, PG is performed for advanced AEG [5]. However, the incidence of LN metastasis is higher in AEG than in non-junctional cancer. Therefore, the oncological safety of PG for AEG still remains unclear.
To perform PG for AEG, at least 2 conditions should be satisfied. First, more than one half of the distal stomach should be preserved with an oncological safety margin of at least 2 cm for T1 tumors, 3 cm for T2 or deeper tumors with an expansive growth pattern (types 1 and 2), and 5 cm for those with an infiltrative growth pattern (types 3 and 4) [4]. Second, no LN metastasis in number 3b station should be detected. In this study, none of the patients with AEG and a gastric invasion length of less than 40 mm had any LN metastases in the number 3b station. Thus, PG may be indicated for patients with AEG with a gastric invasion length of less than 40 mm, if a sufficient distal margin can be obtained while preserving more than half of the stomach. AEG with a gastric invasion length of more than 40 mm would preclude preservation of half of the stomach after PG; therefore, from the viewpoint of function preservation, PG should not be indicated for such cases.

In JGCG 2018 (ver.5), LN dissection of stations number 1, 2, 3, and 7 is recommended for AEGs measuring less than 40 mm in diameter with the lesion center located within 20 mm of the EGJ [4]. This type of AEG was included in AEG with a gastric invasion length of less than 40 mm and was not associated with number 3b LN metastasis in this study. Thus, the recommended extent of LN dissection might be changed to “Number 1, 2, 3a, and 7 stations” and PG might be indicated for both early and advanced AEGs measuring less than 40 mm in diameter with the lesion center located within 20 mm of the EGJ.

Mine et al. investigated whether gastric invasion length of tumor was related to the distribution of involved abdominal lymph nodes in Siewert type II AEG [19]. They used Youden Index and determined the cut-off value of gastric invasion length with regard to nodal involvement and found that the length of 43 mm had the largest sum of sensitivity and specificity. Thus, they divided the patients into three groups according to the gastric invasion length (<30, 30–50, and >50 mm). They found that the distribution of involved abdominal LNs in Siewert type II AEG was significantly related to the gastric invasion length of tumor and concluded that PG can be indicated when the gastric invasion length is ≤30 mm. On the other hand, TG should be considered when the gastric invasion length is >50 mm. PG or TG indication was controversial when gastric invasion length was 30–50 mm.

In our study, the cut-off value of gastric invasion length was 40 mm for the following 2 reasons: first, half of the stomach cannot be preserved with sufficient oncological safety margin after PG for AEG with a gastric invasion length of more than 40 mm; second, JGCG prescribes a tumor measuring less than 40 mm in diameter with the lesion center located within 20 mm of the EGJ as junctional cancer. All these AEG types are included in AEG with a gastric invasion length of less than 40 mm. We considered that 40 mm was the most optimal cut-off value to determine the indications of PG for AEG. Therefore, a new cut-off value of gastric invasion length for PG in AEG might be established.

The present retrospective study had some limitations. First, this study was based on the data of a small number of patients. Although the number of patients with AEG is increasing in Japan, LN stations number 3a and 3b began to be investigated separately after the subclassification of number 3 station into these two substations in March 2010 by the JGCG. The number of patients in this study was too small to examine the IEBLD, a concept proposed by Sasako et al. [20] to assess the efficacy of LN dissection of each LN station. Further large-scale analysis should address this issue. Second, the specimens’ size and length were examined after formalin fixation, which may not exactly match clinical measurements. Moreover, these parameters differ among cases and their accurate measurement was
difficult because we had no reliable method to evaluate gastric invasion length pre- or intraoperatively. Tumor size and esophageal or gastric invasion length are generally measured by endoscopy with or without endoscopic measurement. Accurate measurement of these parameters is difficult because it is endoscopist-dependent and EGJ is sometimes difficult to detect in large tumors. Therefore, differences between clinical and surgical diagnoses generally arise. However, these parameters can be of help in detecting PG candidates.

In conclusion, radical PG may be indicated for patients with AEG with a gastric invasion length of less than 40 mm who do not require number 3b lymphadenectomy.

REFERENCES

1. Yamashita K, Sakuramoto S, Nemoto M, Shibata T, Mieno H, Katada N, et al. Trend in gastric cancer: 35 years of surgical experience in Japan. World J Gastroenterol 2011;17:3390-3397. [PUBMED] [CROSSREF]
2. Kusano C, Gotoda T, Khor CJ, Katai H, Kato H, Taniguchi H, et al. Changing trends in the proportion of adenocarcinoma of the esophagogastric junction in a large tertiary referral center in Japan. J Gastroenterol Hepatol 2008;23:1662-1665. [PUBMED] [CROSSREF]
3. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005;97:142-146. [PUBMED] [CROSSREF]
4. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer 2017;20:1-19. [PUBMED] [CROSSREF]
5. Yoshikawa T, Takeuchi H, Hasegawa S, Nozaki I, Kishi K, Ito S, et al. Theoretical therapeutic impact of lymph node dissection on adenocarcinoma and squamous cell carcinoma of the esophagogastric junction. Gastric Cancer 2016;19:143-149. [PUBMED] [CROSSREF]
6. Hiki N, Nunobe S, Kubota T, Jiang X. Function-preserving gastrectomy for early gastric cancer. Ann Surg Oncol 2013;20:2683-2692. [PUBMED] [CROSSREF]
7. Katai H, Sano T, Fukagawa T, Shinohara H, Sasako M. Prospective study of proximal gastrectomy for early gastric cancer in the upper third of the stomach. Br J Surg 2003;90:850-853. [PUBMED] [CROSSREF]
8. Goto H, Tokunaga M, Miki Y, Makuuchi R, Sugisawa N, Tanizawa Y, et al. The optimal extent of lymph node dissection for adenocarcinoma of the esophagogastric junction differs between Siewert type II and Siewert type III patients. Gastric Cancer 2015;18:375-381. [PUBMED] [CROSSREF]
9. Yamashita H, Katai H, Morita S, Saka M, Taniguchi H, Fukagawa T. Optimal extent of lymph node dissection for Siewert type II esophagogastric junction carcinoma. Ann Surg 2011;254:274-280. [PUBMED] [CROSSREF]
10. Hosoda K, Yamashita K, Moriya H, Mieno H, Watanabe M. Optimal treatment for Siewert type II and III adenocarcinoma of the esophagogastric junction: a retrospective cohort study with long-term follow-up. World J Gastroenterol 2017;23:2723-2730. [PUBMED] [CROSSREF]
11. Hasegawa S, Yoshikawa T, Rino Y, Oshima T, Aoyama T, Hayashi T, et al. Priority of lymph node dissection for Siewert type II/III adenocarcinoma of the esophagogastric junction. Ann Surg Oncol 2013;20:4252-4259. [PUBMED] [CROSSREF]
12. Sano T, Aiko T. New Japanese classifications and treatment guidelines for gastric cancer: revision concepts and major revised points. Gastric Cancer 2011;14:97-100. [PUBMED] [CROSSREF]
13. Sasako M, Shinohara H. Perspective on gastric cancer. In: Zinner MJ, Ashley SW, eds. Maingot’s Abdominal Operations. 12th ed. New York (NY): McGraw-Hill; 2012:489-491.
14. Morita S, Katai H, Saka M, Fukagawa T, Sano T, Sasako M. Outcome of pylorus-preserving gastrectomy for early gastric cancer. Br J Surg 2008;95:1131-1135.

15. Aizawa M, Honda M, Hiki N, Kinoshita T, Yabusaki H, Nunobe S, et al. Oncological outcomes of function-preserving gastrectomy for early gastric cancer: a multicenter propensity score matched cohort analysis comparing pylorus-preserving gastrectomy versus conventional distal gastrectomy. Gastric Cancer 2017;20:709-717.

16. Takiguchi N, Takahashi M, Ikeda M, Inagawa S, Ueda S, Nobuoka T, et al. Long-term quality-of-life comparison of total gastrectomy and proximal gastrectomy by postgastrectomy syndrome assessment scale (PGSAS-45): a nationwide multi-institutional study. Gastric Cancer 2015;18:407-416.

17. Jung DH, Ahn SH, Park DJ, Kim HH. Proximal gastrectomy for gastric cancer. J Gastric Cancer 2015;15:77-86.

18. Nomura E, Okajima K. Function-preserving gastrectomy for gastric cancer in Japan. World J Gastroenterol 2016;22:5888-5895.

19. Mine S, Kurokawa Y, Takeuchi H, Kishi K, Ito Y, Ohi M, et al. Distribution of involved abdominal lymph nodes is correlated with the distance from the esophagogastric junction to the distal end of the tumor in Siewert type II tumors. Eur J Surg Oncol 2015;41:1348-1353.

20. Sasako M, McCulloch P, Kinoshita T, Maruyama K. New method to evaluate the therapeutic value of lymph node dissection for gastric cancer. Br J Surg 1995;82:346-351.